We are registered as an independent intermediary for medicines with the Dutch Ministry of Health
How to buy Taltz:
You can order Taltz (ixekizumab) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.
Eli Lilly and Co.
Mode of Action
Humanised interleukin-17A antagonist
EMA approved (EU); FDA approved (USA); TGA approved (AUS)
Who is ixekizumab for?
Taltz (ixekizumab) is indicated for the treatment of patients with moderate to severe plaque psoriasis  who are candidates for systemic therapy or phototherapy .
Complete information about Taltz (ixekizumab) dosage and administration can be found here: . The standard dosage is:
first dose of 160 mg (two injections)
for the first 12 weeks: an injection of 80 mg every 2 weeks
thereafter an injection of 80 mg every 4 weeks.
Instruction for the use of the prefilled syringe can be found here , whilst instructions for the use of the prefilled pen can be found here . Consult your treating doctor for personalised dosing.
What is ixekizumab and how does it work?
Taltz (ixekizumab) is a monoclonal antibody used to treat adults with moderate to severe plaque psoriasis . The active ingredient in Taltz, ixekizumab, is a humanised interleukin-17A antagonist ; a protein designed to attach to interleukin 17A, a messenger molecule in the immune system. Interleukin 17A is involved in immune system effects, including inflammation, that cause psoriasis. By attaching to interleukin 17A, ixekizumab blocks its action and reduces the activity of the immune system, thereby reducing the symptoms of psoriasis .
for the treatment of adults with moderate to severe plaque psoriasis. The approvals were based on 3 main clinical trials (UNCOVER-1,2,3) involving 3,866 patients with psoriasis . All 3 studies compared ixekizumab administered at a dosage of 80 mg (after an initial injection of 160 mg) every 2 (N = 1169) or every 4 weeks (N= 1165), with placebo (N= 792). Two trials compared ixekizumab also to etanercept (N = 740). The parameters used for the comparison were the static Physician Global Assessment (sPGA) and the Psoriasis Area and Severity Index (PASI). The sPGA is a measure of the status of the psoriatic lesions of a patient (i.e., plaque thickness/induration, erythema, scaling) on a severity scale from 0 (=clear) to 5 (=severe) . The PASI additionally to the severity of the lesions takes into account the body surface area covered with psoriatic lesions . The results presented here are the average across the 3 studies, the complete results can be found here: . After 12 weeks ixekizumab administered every 2 weeks resulted as superior in all the measured parameters to all other tested conditions. The sPGA was equal to 0 (=clear) or 1 (=almost clear) in 81.8 % of the patients treated with ixekizumab every 2 weeks and almost 40 % of these had clear skin (sPGA =1 in 39.7 % of the patients and 37.8 % had a reduction of 100 % in PASI). On the other hand the sPGA was equal to 0 or 1 in 74.9 % of the patients treated with ixekizumab every 4 weeks, 38.8 % of those treated with etanercept and 4.1 % in the placebo cohort . Almost 89 % of those treated every two weeks with ixekizumab attained a 75 % reduction in the PASI after 12 weeks, which compares with 82.5 % of the patients on ixekizumab every 4 weeks, 47.5 % of patients on etanercept, and 4.5 % of those given placebo . To evaluate the maintenance and durability of the response, two studies continued for an additional 48 weeks in patients who at week 12 had responded to ixekizumab (both those on the biweekly plan and those on the monthly plan). These patients were randomly assigned to a maintenance dosage of ixekizumab every 4 weeks or to placebo. The best results were obtained in patients who took ixekizumab every 2 weeks for the first 12 weeks and every 4 weeks for the following 48 weeks. In this cohort, 78.3 % of the patients maintained a sPGA of 0 or 1, and about 58 % of these had maintained or achieved clear skin (sPGA = 0 in 58.8 % and 100 % reduction in PASI in 57.5 %). On the other hand, only about 7 % of the initial responders that switched to placebo had a sPGA of 0 or 1 , meaning that most of them relapsed after interruption of the treatment with ixekizumab.
Buyer There is a 6% tax on medicines + 21% tax on shipping for EU individuals
Shipping Cost Estimate
*Once you provide us with the exact shipping address, the actual price may vary.
Send this price estimate to your email address
Ordering with TheSocialMedwork is a safe and legal way to import a prescription medicine that has been approved in another country, but is not yet available where you live.
If you think that this medicine may be suitable for treating your condition, get in touch.
We'll answer any questions you might have and provide you with further information. Select the
tab to get a close estimate of the full cost of the medicine including delivery.
If you would like us to provide you with a precise quote we'll need to know the exact address of where you want us to send your medicine to.
2. Chat with your doctor
About whether this treatment might be suitable for you. In order to place an order with us, you’ll need to provide us with a prescription from your doctor who must be based in the same country where the medicine will be shipped to.
3. Place your order
Once you have your doctor's prescription you’re ready to place an order with us. Payment can be made by credit card, electronic bank transfer or Paypal.
As soon as we receive your payment we’ll process your order and your medicine will be shipped to you via a pharmacy.
Delivery time can vary from country to country but usually takes 1 to 3 weeks.
We'll send you a tracking number and keep you up to date on the status of your order.
Rest assured that we'll guide you through the entire process.
We'll let you know exactly what regulations need to be followed and the specific documentation you'll need to import the medicine into your country so that you get your treatment as quickly as possible. Ask us a question
"TheSocialMedwork helped us to get the medicine, which was not accessible for us, in the shortest possible time."
- Haoyu, China.
Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision.
Terms and Conditions